Loading…
Chinese maker of recombinant proteins, antibodies and reagents used in life-science research.
Chinese maker of recombinant proteins, antibodies and reagents used in life-science research.
In one line: A China-based life-science reagents supplier.
Moat: narrow (scale, process know-how). Broad reagent catalog and manufacturing scale versus smaller domestic peers.
Headquarters: Suzhou, China · Employees: 636
Size Suzhou Novoprotein Scientific (688137.SS) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $1.33B, the 1822nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥126.60 on 6 Nov 2026.
Performance Over six months the shares gained 161.1%, against -11.7% for the median peer and -16.4% for the China market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 8.1% over the last twelve months (peer median +9.5%); the operating margin is -61.6% (peer median 9.3%).
Valuation It trades at 51.3× enterprise value to sales against a peer median of 2.8× (most expensive of 21).
Capital Return on invested capital runs 14.9 points below its cost of capital (10.6% WACC).
Next results Next results expected around 4 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥159M | CN¥146M | CN¥126M | CN¥153M | CN¥262M |
| Revenue growth | — | +15% | -17% | -42% | — |
| Gross profit | CN¥126M | CN¥81.7M | CN¥60.3M | CN¥105M | CN¥216M |
| EBITDA | n/a | -CN¥59.2M | -CN¥63.4M | -CN¥25.7M | CN¥104M |
| Net income | -CN¥96.8M | -CN¥77.8M | -CN¥54.4M | CN¥12.8M | CN¥90.7M |
| Free cash flow | -CN¥173M | -CN¥61.2M | -CN¥15.4M | CN¥44.3M | -CN¥32.8M |
| Capital expenditure | CN¥164M | CN¥78.9M | CN¥44.9M | CN¥44.9M | CN¥36.8M |
| Total debt | CN¥47.8M | CN¥55.6M | CN¥66.4M | CN¥73.3M | CN¥83.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688137.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.6% | -5.8% | 4th lowest of 21 |
| 6-month return | +161.1% | -11.7% | highest of 21 |
| Distance from 52-week high | -24.7% | -35.4% | 6th highest of 21 |
| Revenue growth (TTM) | +8.1% | +9.5% | 10th lowest of 21 |
| Operating margin | -61.6% | 9.3% | lowest of 21 |
| EV / Sales | 51.3× | 2.8× | most expensive of 21 |
| ROIC minus cost of capital | -14.9 pp | +0.7 pp | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Suzhou Novoprotein Scientific 688137.SS | China | $1.33B | +161% | +8% | -62% | 51.3× | n/a | n/a |
| Central Mine Planning & Design Institute CMPDI.NS | India | $1.34B | -15% | +10% | 33% | 4.8× | 4.0% | +18.7% |
| Nittetsu Mining 1515.T | Japan | $1.34B | +10% | +13% | 9% | 1.1× | n/a | n/a |
| TKC 9746.T | Japan | $1.34B | +21% | +14% | 22% | 1.9× | -9.9% | +4.2% |
| Changchun Up Optotech 002338.SZ | China | $1.34B | -39% | +22% | 2% | 11.0× | n/a | n/a |
| SBS 2384.T | Japan | $1.38B | +32% | +22% | 6% | 0.6× | -8.2% | +13.8% |
| Bajaj Mobility BMAG.SW | Switzerland | $1.28B | +86% | -47% | -44% | 1.9× | n/a | n/a |
| Shanghai MicroPort EP Medtech 688351.SS | China | $1.27B | -23% | +20% | 3% | 13.3× | 41.7% | +26.7% |
| China Security 600654.SS | China | $1.39B | -31% | -30% | -1% | 3.7× | 56.7% | +0.4% |
| Wintech Nano (Suzhou) 688757.SS | China | $1.39B | -18% | +23% | 7% | 16.4× | n/a | n/a |
| Concord Biotech CONCORDBIO.NS | India | $1.40B | +2% | +4% | 28% | 10.9× | 47.1% | +11.6% |
| Siglent Technologies 688112.SS | China | $1.41B | -5% | +30% | 24% | 11.0× | 31.3% | +22.0% |
| China National Electric Apparatus Research Institute 688128.SS | China | $1.42B | -12% | +8% | 11% | 1.7× | 4.0% | +13.5% |
| CRA International CRAI | United States | $1.24B | +42% | +11% | 10% | 1.9× | n/a | n/a |
| Derichebourg DBG.PA | France | $1.42B | -24% | -3% | 5% | 0.6× | 6.8% | +6.3% |
| Shanxi Huaxiang 603112.SS | China | $1.24B | -26% | +9% | 11% | 1.9× | 1.4% | +16.2% |
| ICF International ICFI | United States | $1.43B | +14% | -8% | 8% | 1.0× | -2.2% | +4.4% |
| Vcanbio Cell & Gene Engineering 600645.SS | China | $1.23B | -32% | -6% | 12% | 4.7× | 11.0% | +1.9% |
| Jadard Technology 688252.SS | China | $1.22B | -12% | +6% | 12% | 2.7× | 13.3% | +31.3% |
| Resolute Holdings Management RHLD | United States | $1.20B | +39% | +10% | 9% | 5.7× | 26.0% | n/a |
| Suzhou Recodeal Interconnect System 688800.SS | China | $1.47B | -55% | +5% | 9% | 3.0× | 26.1% | +38.9% |